Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9355
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alaçam, Hüseyin | - |
dc.contributor.author | Akgün, Şakir | - |
dc.contributor.author | Akça, Hakan | - |
dc.contributor.author | Öztürk, Önder | - |
dc.contributor.author | Kabukçu, Bürge Başay | - |
dc.contributor.author | Herken, Hasan | - |
dc.date.accessioned | 2019-08-16T13:00:09Z | |
dc.date.available | 2019-08-16T13:00:09Z | |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0165-1781 | - |
dc.identifier.uri | https://hdl.handle.net/11499/9355 | - |
dc.identifier.uri | https://doi.org/10.1016/j.psychres.2016.08.037 | - |
dc.description.abstract | The aim of the study was to determine the differences between expression levels of certain miRNAs, as their association with schizophrenia has been well presented in the literature, and to investigate their relation to treatment resistance in schizophrenic patients. Three groups were formed: 1) treatment-resistant group, 2) treatment responsive group and 3) healthy control group. Expression levels of miRNAs from peripheric blood samples were determined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). We investigated the roles of 29 schizophrenia-related miRNAs in schizophrenia treatment and their potentials to be considered as indicators. Among these miRNAs, only miR-181b-5p, miR-195-5p and miR-301a-3p expressions were found to be significantly different between the treatment-resistant group and the group responding well to the treatment. miRNAs may cause resistance by silencing the receptor genes of the drugs used for schizophrenia treatment. miR-181b-5p, miR-195-5p and miR-301a-3p may be candidate indicators that can be used to reveal resistance against schizophrenia treatment. © 2016 Elsevier Ireland Ltd | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ireland Ltd | en_US |
dc.relation.ispartof | Psychiatry Research | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | MiR-181b-5p | en_US |
dc.subject | MiR-195-5p | en_US |
dc.subject | MiR301a-3p | en_US |
dc.subject | Schizophrenia | en_US |
dc.subject | Treatment-resistant schizophrenia | en_US |
dc.subject | chlorpromazine | en_US |
dc.subject | haloperidol | en_US |
dc.subject | microRNA | en_US |
dc.subject | microRNA 181b 5p | en_US |
dc.subject | microRNA 195 5p | en_US |
dc.subject | microRNA 301 3p | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | neuroleptic agent | en_US |
dc.subject | adult | en_US |
dc.subject | Article | en_US |
dc.subject | blood sampling | en_US |
dc.subject | clinical article | en_US |
dc.subject | clinical effectiveness | en_US |
dc.subject | controlled study | en_US |
dc.subject | disease association | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | drug response | en_US |
dc.subject | female | en_US |
dc.subject | gene expression | en_US |
dc.subject | gene function | en_US |
dc.subject | gene identification | en_US |
dc.subject | human | en_US |
dc.subject | male | en_US |
dc.subject | molecular dynamics | en_US |
dc.subject | outcome assessment | en_US |
dc.subject | priority journal | en_US |
dc.subject | quantitative analysis | en_US |
dc.subject | real time polymerase chain reaction | en_US |
dc.subject | receptor gene | en_US |
dc.subject | reverse transcription polymerase chain reaction | en_US |
dc.subject | schizophrenia | en_US |
dc.subject | case control study | en_US |
dc.subject | drug resistance | en_US |
dc.subject | gene expression profiling | en_US |
dc.subject | gene silencing | en_US |
dc.subject | genetics | en_US |
dc.subject | middle aged | en_US |
dc.subject | Adult | en_US |
dc.subject | Antipsychotic Agents | en_US |
dc.subject | Case-Control Studies | en_US |
dc.subject | Drug Resistance | en_US |
dc.subject | Female | en_US |
dc.subject | Gene Expression Profiling | en_US |
dc.subject | Gene Silencing | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | MicroRNAs | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Real-Time Polymerase Chain Reaction | en_US |
dc.title | miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 245 | en_US |
dc.identifier.startpage | 200 | |
dc.identifier.startpage | 200 | en_US |
dc.identifier.endpage | 206 | en_US |
dc.authorid | 0000-0001-8247-9702 | - |
dc.authorid | 0000-0002-9477-8571 | - |
dc.authorid | 0000-0003-4124-2340 | - |
dc.identifier.doi | 10.1016/j.psychres.2016.08.037 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 27552670 | en_US |
dc.identifier.scopus | 2-s2.0-84982311237 | en_US |
dc.identifier.wos | WOS:000386741600029 | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.owner | Pamukkale University | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
36
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
33
checked on Nov 21, 2024
Page view(s)
58
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.